{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:23:51Z","timestamp":1790508231320,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>177Lu-PSMA-617 (LuPSMA) is an approved prostate-specific membrane antigen (PSMA)\u2013targeted radiopharmaceutical therapy for men with metastatic castration-resistant prostate cancer (mCRPC). Older patients, particularly octogenarians, represent a substantial proportion of men with mCRPC but have been traditionally underrepresented in key registrational trials of LuPSMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This retrospective multi-institutional study evaluated patients age 80 years and older with mCRPC after chemotherapy treated with \u22651 cycle of LuPSMA from August 2022 to December 2024. Clinical and demographic data were abstracted from electronic medical records. Outcomes included prostate specific antigen (PSA) response (PSA50 and PSA90), progression-free survival (PFS), overall survival (OS), and toxicities. Kaplan-Meier methods estimated PFS\/OS; descriptive statistics summarized baseline and safety data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Ninety-five patients (median age, 83 years) were included, of whom 36 (38%) and 21 (22%) had a history of cardiac disease or chronic kidney disease, respectively. Median follow-up was 24.1 months (IQR, 6.7-28.1). Patients received a median of five cycles of LuPSMA. Fifty-two (57%) and 21 (23%) patients achieved a PSA50 and PSA90, respectively. Median PFS and OS were 7.3 months (95% CI, 6.4 to 8.7) and 13.5 months (95% CI, 9.7 to 18.8), respectively. Grade \u22653 hematologic toxicities included anemia (n = 19; 20%) and thrombocytopenia (n = 4, 4%); grade \u22653 acute kidney injury occurred in one patient. Fourteen (15%) patients had dose delays, seven (7%) required reductions, and 10 (11%) discontinued therapy due to toxicity. Thirty-seven patients (39%) were hospitalized during therapy, with intensive care unit-level care required in two patients (2%), and there was one treatment-related death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>LuPSMA had comparable outcomes in octogenarians with mCRPC to patients on registrational trials, although 2\/5 of patients required hospitalization during therapy. These findings support the feasibility and efficacy of LuPSMA in well-selected older men with mCRPC and suggest a role for closer monitoring of older patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-01161","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T19:59:21Z","timestamp":1777060761000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7318-0888","authenticated-orcid":true,"given":"Daniel","family":"Sentana-Lledo","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5509-6033","authenticated-orcid":true,"given":"Avina","family":"Rami","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9561-1439","authenticated-orcid":true,"given":"Caiwei","family":"Zhong","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7268-5077","authenticated-orcid":true,"given":"Miguel","family":"Muniz","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-8000","authenticated-orcid":true,"given":"Wanling","family":"Xie","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4664-9296","authenticated-orcid":true,"given":"Elizabeth","family":"Tchitchkan","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey","family":"Stoltenberg","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4249-0311","authenticated-orcid":true,"given":"Irbaz Bin","family":"Riaz","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wolanski","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"},{"name":"Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolivette","family":"Ritzer","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"},{"name":"Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-078X","authenticated-orcid":true,"given":"Heather","family":"Jacene","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"},{"name":"Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0097-1574","authenticated-orcid":true,"given":"Kerry","family":"Schaffer","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, TN"},{"name":"Veteran Administration Tennessee Valley VA Health Care System Geriatric Research Education Clinical Center (GRECC), Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7643-2836","authenticated-orcid":true,"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7466-4702","authenticated-orcid":true,"given":"Praful","family":"Ravi","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34749"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.07.018"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00801-w"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265259"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.2174\/0118744710284661240328094119"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0100"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00725-8"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390396"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2024.101720"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2025.01.001"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000363708"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2019.03.001"},{"key":"e_1_3_7_16_2","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0","author":"U.S. Department of Health and Human Services.","year":"2017","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. National Cancer Institute (NCI), 2017"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"e_1_3_7_18_2","unstructured":"SAS: Data and AI solutions. https:\/\/www.sas.com\/en_us\/home.html"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00933"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103657"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000740"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgac017"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265194"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.7150\/thno.108963"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-01161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T19:59:23Z","timestamp":1777060763000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-01161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":23,"alternative-id":["10.1200\/OP-25-01161"],"URL":"https:\/\/doi.org\/10.1200\/op-25-01161","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"2025-10-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-25-01161"}}